Company to Expand Patented Wellness Approach into High-Growth Cognitive and Restorative Sleep Markets, Emphasizing Scientific Rigor and Unique Formulations SCOTTSDALE, AZ, June 03, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company known for Sure Shot™, its patented product that rapidly lowers blood alcohol content by supporting its metabolism, today announced the initiation of research and development (R&D) for innovative ne ...

NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board: Scott A. Sands, Ph.D., Associate Professor of Medicine at Harvard Medical School and Director of the Sleep Apnea Translational Physi ...

Company Overview - Nyxoah is a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA) [4] - The company's lead product is the Genio® system, which is a leadless and battery-free hypoglossal neurostimulation therapy for OSA [4] Recent Developments - Nyxoah will participate in the Jefferies Global Healthcare Conference from June 3 to June 5, 2025, in New York [2] - CEO Olivier Taelman will present on June 4, 2025, at 4:55 PM ET, with a webcast available on the company's Investor Relations website [3] - The company will also hold one-on-one meetings with institutional investors during the conference [3] Product Milestones - The Genio® system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [5] - Nyxoah has completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021 [5] - The company received CE mark approval for expanded therapeutic indications to treat Complete Concentric Collapse (CCC) patients, which are currently contraindicated in competitors' therapies [5] - Positive outcomes from the DREAM IDE pivotal study have also been announced [5]

Financial Data and Key Metrics Changes - The company's net revenues for Q1 2025 grew by 29.8% year over year but fell by 8.6% quarter over quarter [28] - Adjusted net income for Q1 2025 was RMB 345 million, representing a 32.3% increase year over year [33] - Adjusted EBITDA for Q1 2025 was up by 33.8% year over year [33] - Gross margin of hotel businesses expanded to 36.6% in Q1 2025 from 34.1% in the same period of 2024 [30] - Gross margin of retail business expanded to 51.4% in Q1 2025 from 50.5% in the same period of 2024 [31] Business Line Data and Key Metrics Changes - Hotel operating costs increased by 11.2% year over year due to variable costs associated with hotel network expansion [30] - Revenues from monetized hotels were RMB 1,032 million, up by 23.5% year over year [28] - Retail business revenue reached RMB 845 million, up 70.9% year over year [17] Market Data and Key Metrics Changes - RevPAR reached RMB 304.4 in Q1 2025, representing 92.8% of its level in the same period of 2024 [7] - Occupancy rate (OCC) reached 95.8% and Average Daily Rate (ADR) stood at 97.2% compared to the same period in 2024 [8] Company Strategy and Development Direction - The company is committed to advancing the strategic initiative of establishing 2,000 premier hotels, enhancing brand awareness and product offerings [6][7] - Focus on product innovation and experiential upgrades to cater to younger consumers in the midscale segment [14][15] - The company aims to maintain a balance between quality and expansion, ensuring sustainable high-quality growth [10][47] Management's Comments on Operating Environment and Future Outlook - The management noted fluctuations in China's domestic travel market amid a complex macro environment, presenting both challenges and opportunities [6] - There is an expectation of easing RevPAR pressure in Q2 compared to Q1, but considerable uncertainty remains for the full year [40] - The company plans to adopt a more balanced revenue management strategy to build long-term brand value [41] Other Important Information - The company declared its first cash dividend in 2025 of US$0.14 per ordinary share, totaling approximately US$58 million [34] - A three-year share repurchase program was announced, allowing for repurchases of up to US$400 million [34] Q&A Session Summary Question: Performance of RevPAR since Q2 and outlook for the full year - Management indicated that RevPAR decreased by 7.2% year over year in Q1, with expectations of easing pressure in Q2, but full-year performance remains uncertain [38][40] Question: New signings momentum and hotel openings for 2025 - Management confirmed a positive signing momentum and maintained a full-year opening guidance of 500 new hotels [43][46] Question: Update on retail business revenue growth and full-year guidance - Management raised the full-year retail revenue growth forecast to 50% year over year, citing strong performance and product launches [50][52] Question: Considerations behind dividend and share buyback program - Management emphasized a commitment to long-term value creation and rewarding shareholders through dividends and share repurchases [55][57] Question: Progression of upscale brands and new product strategies - Management announced the upcoming opening of the Sahe flagship hotel and detailed strategies for the upper midscale and midscale segments [61][63]

Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of ...

SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings rugby fans’ dreams to life over a six-week period. For the first time in 12 years, The Lions squad, alongside an estimated 40,000 fans, will battle it out with the Wallabies, Super Rugby ...

Core Insights - Nyxoah is on track for anticipated PMA approval of its Genio® system in the second quarter of 2025, having successfully completed FDA validation requirements and currently undergoing final site inspection [2][4][17] - The company reported a revenue of €1.1 million for Q1 2025, a decrease from €1.2 million in Q1 2024, with a gross profit margin of 61.8% [5][10][11] - Significant increases in research and development expenses (€9.0 million) and selling, general and administrative expenses (€12.4 million) were noted, contributing to an operating loss of €20.6 million for Q1 2025 [12][13][14] Financial Performance - Revenue for Q1 2025 was €1.1 million, down from €1.2 million in Q1 2024 [10] - Cost of goods sold was €406,000, resulting in a gross profit of €658,000 [11] - Research and development expenses rose to €9.0 million from €7.2 million year-over-year [12] - Selling, general and administrative expenses increased to €12.4 million from €6.0 million year-over-year [13] - The operating loss for Q1 2025 was €20.6 million, compared to €12.2 million in Q1 2024 [14] Cash Position - As of March 31, 2025, cash, cash equivalents, and financial assets totaled €63.0 million, down from €85.6 million at the end of 2024 [15] Regulatory Progress - The FDA issued an Approvable Letter for Nyxoah's PMA application for the Genio® system, indicating that the application meets the necessary requirements [6][17] - The final step before full PMA approval is an on-site inspection of the U.S. manufacturing site, which has already passed a previous inspection with no deficiencies [4][18] Company Overview - Nyxoah focuses on developing innovative solutions for Obstructive Sleep Apnea (OSA), with its lead product being the Genio® system, a hypoglossal neurostimulation therapy [21] - The company received its European CE Mark for the Genio® system in 2019 and has conducted successful IPOs on Euronext Brussels and NASDAQ [22]

– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing med ...

LivaNova (LIVN) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Briana Gotlin - VP-IRVladimir Makatsaria - CEOAhmet Tezel - Chief Innovation OfficerAlex Shvartsburg - Chief Financial OfficerRick Wise - Managing Director - Medical Technology & SuppliesDavid Roman - Managing DirectorStephanie Bolton - President of Global Epilepsy Conference Call Participants Adam Maeder - Senior Research AnalystMichael Sarcone - AnalystMike Matson - Senior Equity Research AnalystDavid Rescott - Senior Rese ...

Purple Innovation (PRPL) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Stacy Turnof - EVP - Strategic Situations & Investor RelationsRobert DeMartini - CEO & DirectorTodd Vogensen - Chief Financial OfficerBobby Griffin - Managing Director Conference Call Participants Bradley Thomas - Managing Director & Equity Research AnalystDan Silverstein - Equity Research AnalystBrian Nagel - MD & Senior Analyst - Consumer Growth & eCommerceNone - Analyst Operator Ladies and gentlemen, thank you fo ...